Overview

• The REDEFINE 1 sub‑analysis found once‑weekly cagrilintide 2.4 mg cut body weight by an average 11.8% at 68 weeks versus 2.3% with placebo, with 31.6% achieving at least 15% loss.
• Cagrilintide was generally well‑tolerated, with mostly transient, mild‑to‑moderate gastrointestinal events, and nausea led to discontinuation in 1.0% on drug versus 0.1% on placebo.
• Novo Nordisk will start the dedicated phase 3 RENEW program in the fourth quarter of 2025 to further evaluate cagrilintide in people with overweight or obesity.
• Cagrilintide is a long‑acting amylin analogue that acts via a mechanism distinct from GLP‑1 therapies such as semaglutide.
• Company leaders said they intend to seek U.S. approval for a higher‑dose Wegovy and described plans to study future weight‑loss drugs across obesity‑linked conditions, while shares rose after the data release.